会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明申请
    • N-(4-OXO-3,4-DIHYDROQUINAZOLIN-2-YL)BUTANAMIDES AS ANDROGEN RECEPTOR MODULATORS
    • N-(4-氧代-3,4-二氢喹唑啉-2-基)丁酸钠作为雄激素受体调节剂
    • WO2007038444A2
    • 2007-04-05
    • PCT/US2006/037273
    • 2006-09-22
    • MERCK & CO., INC.HANNEY, BarbaraKIM, YuntaeMITCHELL, Helen, J.MUSSELMAN, Jeffrey, D.PERKINS, James, J.
    • HANNEY, BarbaraKIM, YuntaeMITCHELL, Helen, J.MUSSELMAN, Jeffrey, D.PERKINS, James, J.
    • A61K31/517
    • C07D403/06C07D239/90C07D409/12
    • Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer’s disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.
    • 结构式I的化合物是以组织选择性方式的雄激素受体(AR)的调节剂。 这些化合物可用于增强弱化肌张力和治疗由雄激素缺乏引起的疾病或可由雄激素给药改善的疾病,包括骨质疏松症,骨质减少,糖皮质激素诱导的骨质疏松症,牙周病,骨折,骨重建后的骨损伤 手术,肌营养不良,虚弱,老化的皮肤,男性性腺机能减退,女性绝经后症状,动脉粥样硬化,高胆固醇血症,高脂血症,肥胖,再生障碍性贫血和其他造血障碍,炎症性关节炎和关节修复,HIV消耗,前列腺癌,良性前列腺增生 ),腹部肥胖,代谢综合征,II型糖尿病,癌症恶病质,阿尔茨海默氏病,肌营养不良症,认知衰退,性功能障碍,睡眠呼吸暂停,抑郁症,早期卵巢衰竭和自身免疫性疾病,单独或与其它活性剂组合。
    • 4. 发明申请
    • N-(PYRIDIN-4-YL)-2-PHENYLBUTANAMIDES AS ANDROGEN RECEPTOR MODULATORS
    • N-(PYRIDIN-4-YL)-2-苯基琥珀酸作为雄激素受体调节剂
    • WO2007016358A1
    • 2007-02-08
    • PCT/US2006/029457
    • 2006-07-28
    • MERCK & CO., INC.MEISSNER, Robert, S.PERKINS, James, J.KIM, YuntaeHANNEY, BarbaraMCVEAN, Carol, A.
    • MEISSNER, Robert, S.PERKINS, James, J.KIM, YuntaeHANNEY, BarbaraMCVEAN, Carol, A.
    • C07D211/72C07D211/78A61K31/44
    • C07D213/61A61K31/44C07D213/64C07D213/65Y02A50/401
    • Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer’s disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.
    • 结构式I的化合物是以组织选择性方式的雄激素受体(AR)的调节剂。 这些化合物可用于增强弱化肌张力和治疗由雄激素缺乏引起的疾病或可由雄激素给药改善的疾病,包括骨质疏松症,骨质减少,糖皮质激素诱导的骨质疏松症,牙周病,骨折,骨重建后的骨损伤 手术,肌营养不良,虚弱,老化的皮肤,男性性腺机能减退,女性绝经后症状,动脉粥样硬化,高胆固醇血症,高脂血症,肥胖,再生障碍性贫血和其他造血障碍,炎症性关节炎和关节修复,HIV消耗,前列腺癌,良性前列腺增生 ),腹部肥胖,代谢综合征,II型糖尿病,癌症恶病质,阿尔茨海默氏病,肌营养不良症,认知衰退,性功能障碍,睡眠呼吸暂停,抑郁症,早期卵巢衰竭和自身免疫性疾病,单独或与其它活性剂组合。
    • 5. 发明申请
    • CARBONYLAMINO-BENZIMIDAZOLE DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS
    • 作为雄激素受体调节剂的羧苄基苯并咪唑衍生物
    • WO2004041277A1
    • 2004-05-21
    • PCT/US2003/034345
    • 2003-10-28
    • MERCK & CO., INC.KIM, YuntaeSPENCER, Keith, L.HANNEY, BarbaraDUGGAN, Mark, E.
    • KIM, YuntaeSPENCER, Keith, L.HANNEY, BarbaraDUGGAN, Mark, E.
    • A61K31/427
    • C07D417/04C07D401/04C07D403/04C07D417/14
    • Compounds of structural formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and/or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient. These compounds are therefore useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, arthritic condition and joint repair, HIV-wasting, prostate cancer, cancer cachexia, Alzheimer s disease, muscular dystrophies, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.
    • 结构式(I)的化合物是以组织选择性方式的雄激素受体(AR)的调节剂。 它们可用作骨和/或肌肉组织中雄激素受体的激动剂,同时拮抗男性患者的前列腺中或在女性患者的子宫中的AR。 因此,这些化合物可用于增强减弱的肌肉紧张度和治疗由雄激素缺乏引起的或由雄激素给药引起的疾病的治疗,包括骨质疏松症,骨质减少,糖皮质激素诱导的骨质疏松症,牙周病,骨折,骨骼骨损伤 重建手术,肌肉减少症,脆弱性,皮肤老化,男性性腺机能减退,女性绝经后症状,动脉粥样硬化,高胆固醇血症,高脂血症,肥胖,再生障碍性贫血和其他造血障碍,关节炎病症和关节修复,艾滋病毒消耗,前列腺癌,癌症恶病质,阿尔茨海默病 疾病,肌营养不良,卵巢早衰,自身免疫疾病,单独或与其他活性剂组合。